VNDA FY2025 SEC EDGAR DEF 14A #165 of 168 in industry

Vanda Pharmaceuticals Inc. CEO pay ratio

The CEO earned $3.9M in FY2025 against median worker pay of $166,623 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
DE
Filing date
2026-04-23
Industry
Chemicals & Pharmaceuticals
Industry rank
#165/168

Data updated August 2026

Subscribe to Vanda Pharmaceuticals Inc. CEO pay filing updates (RSS)

CEO-to-worker pay ratio
1:1
Below Average (Scale: 0–1000:1)
CEO pay
$3.9M
Median worker
$166,623

Answer first

Vanda Pharmaceuticals Inc.'s FY2025 CEO total of $3.9M ranks #1010 of 1,423 complete filings; its 1:1 pay ratio ranks #1409. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $166,623. Industry placement uses the FY2025 SIC-28 peer cohort (# 165 of 168, 2nd percentile - among the lower quartile of industry peers by pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#1010
$3.9M of 1,423 FY2025
Ratio rank
#1409
1:1 of 1,423
Industry pct
2nd
among the lower quartile of industry peers by pay ratio

How Vanda Pharmaceuticals Inc. ranks nationally

Vanda Pharmaceuticals Inc. CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$3,851,468 29th percentile higher than 29% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). This entry sits in this band. $5,000,000–$7,500,000: 208 companies (15%). Above this entry. $7,500,000–$10,000,000: 192 companies (13%). Above this entry. $10,000,000–$12,500,000: 139 companies (10%). Above this entry. $12,500,000–$15,000,000: 91 companies (6%). Above this entry. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Vanda Pharmaceuticals Inc. vs. Chemicals & Pharmaceuticals peers

CEO total pay ($3.9M) against pay ratio (1:1) for Vanda Pharmaceuticals Inc. (marked) and its 4 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both02798065.35596130.68394195.911192261.30:111.0:122.0:133.0:144.0:1CEO total payPay ratio (CEO : median worker)Vanda Pharmaceuticals Inc., CEO total pay: 3851468 · Pay ratio (CEO : median worker): 1:1Vanda Pharmaceuticals Inc.Spyre Therapeutics, Inc., CEO total pay: 437242 · Pay ratio (CEO : median worker): 1:1Spyre Therapeutics, Inc.Zai Lab Ltd, CEO total pay: 10677221 · Pay ratio (CEO : median worker): 1:1Zai Lab LtdTwist Bioscience Corp, CEO total pay: 376416 · Pay ratio (CEO : median worker): 2:1Twist Bioscience CorpSummit Therapeutics Inc., CEO total pay: 1025895 · Pay ratio (CEO : median worker): 3:1Summit Therapeutics Inc.
Vanda Pharmaceuticals Inc. vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Vanda Pharmaceuticals Inc.'s structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Vanda Pharmaceuticals Inc.

Complete DEF 14A pay-ratio filings for this CIK across FY2022–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
1:1
FY2025
vs prior FY
-8:1
from FY2024 9:1
CEO $ YoY
+1965%
$3.9M latest
Filings shown
4
FY2022–2025
Vanda Pharmaceuticals Inc. CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2022 $4.3M - $187,225 8:1 -
2023 $3.7M -13% $193,854 2:1 -6:1
2024 $187K -95% $186,541 9:1 +7:1
2025 $3.9M +1965% $166,623 1:1 -8:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1347178, FY2022–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
1:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$3.9M
Companies in Industry
168
vs. Industry Median
Below
#165 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Vanda Pharmaceuticals Inc.: near-parity Item 402(u) ratio

Vanda Pharmaceuticals Inc.'s FY2025 ratio 1:1 ranks #165 of 168 Chemicals & Pharmaceuticals filers (2nd percentile). the CEO earned 1× the median employee ($166,623) in FY2025.

At $166,623 median worker pay, the PARITY stamp is near pay-parity territory under MID$ CEO total.

CEO Total Pay

$3.9M

FY2025 Summary Compensation, below median

Pay Ratio

1:1

Below typical

Vanda Pharmaceuticals Inc. in the lower Chemicals & Pharmaceuticals third

Vanda Pharmaceuticals Inc.'s FY2025 ratio 1:1 ranks #165 of 168 Chemicals & Pharmaceuticals filers (2nd percentile). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Vanda Pharmaceuticals Inc.'s $3.9M CEO total is at or below the $7.9M industry median CEO pay.

Dollar rank #1010 and ratio rank #1409 split - treat 1:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$3.9M
Median Employee Pay
$166,623
Pay Ratio
1:1
Filing Date
2026-04-23

Company Info

Ticker
VNDA
CIK
1347178
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
DE
View SEC filings →
SEC EDGAR DEF 14A for CIK 1347178, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Vanda Pharmaceuticals Inc.'s FY2025 ratio 1:1 ranks #165 of 168 Chemicals & Pharmaceuticals filers (2nd percentile).

Read with Vanda Pharmaceuticals Inc.

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps PARITY · MID$ · ELITE-MED.

Cava Group, Inc. · MID$

ABS(ceo_total_comp) peer at $3.8M (Δ $3K lighter vs Vanda Pharmaceuticals Inc.); STEEP · LOW-MED vs this page's PARITY · MID$ · ELITE-MED.
Carriage Services Inc · MID$

ABS(ceo_total_comp) peer at $3.9M (Δ $9K heavier vs Vanda Pharmaceuticals Inc.); MID · LOW-MED vs this page's PARITY · MID$ · ELITE-MED.
Integer Holdings Corp · MID$

ABS(ceo_total_comp) peer at $3.8M (Δ $20K lighter vs Vanda Pharmaceuticals Inc.); MID · PAR-MED vs this page's PARITY · MID$ · ELITE-MED.
Loar Holdings Inc. · MID$

ABS(ceo_total_comp) peer at $3.9M (Δ $33K heavier vs Vanda Pharmaceuticals Inc.); MID · PAR-MED vs this page's PARITY · MID$ · ELITE-MED.
Spyre Therapeutics, Inc. (SIC 28 pole)

Spyre Therapeutics, Inc. stamps PARITY · MICRO nearest in-SIC by ABS(pay_ratio) to Vanda Pharmaceuticals Inc.'s PARITY filing.
National dual ranks · #1010/#1409

Vanda Pharmaceuticals Inc.'s FY2025 package sits #1010 by CEO dollars and #1409 by ratio under MID$ · PARITY.
Ratio primer · PARITY

Vanda Pharmaceuticals Inc.'s PARITY stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Vanda Pharmaceuticals Inc. (CIK 1347178), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.